Insignis Therapeutic Receives FDA Feedback on IN-001 Program
05 Nov 2024 //
GLOBENEWSWIRE
Insignis Reports Positive Phase 1 Results For Epinephrine Spray
07 Oct 2024 //
GLOBENEWSWIRE
Insignis Therapeutics Gets FDA Fast Track For IN-001 In Anaphylaxis
13 Aug 2024 //
GLOBENEWSWIRE